Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Breast 2

Conditions

Solid Tumor 7Ovarian Neoplasms 4Prostatic Neoplasms 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Fallopian Tube Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 100liposomal doxorubicin 100Cyclophosphamide 94Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 39Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × senaparib × Clear all
NCT04089189 2026-01-28

SABRINA

Impact Therapeutics, Inc.

Phase 2 Completed
93 enrolled
Gynecologic

Ovarian Neoplasms

NCT06617923 2025-10-27

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
18 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03507543 2021-03-30

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

Impact Therapeutics, Inc.

Phase 1 Completed
39 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT03508011 2021-03-30

A Study of IMP4297 in Patients With Advanced Solid Tumors

Impact Therapeutics, Inc.

Phase 1 Completed
57 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡